A gradual phase-out of co-proxamol led to 350 fewer suicides and accidental deaths in England and Wales, a study in the British Medical Journal reports.

Regulators removed the drug's licence in 2007 after fears about the risk of overdose but the move proved unpopular with some patients and doctors.

Over the two-year period, deaths from co-proxamol fell by 62%.